Novartis receives FDA approval for Rhapsido (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)

Press/Media

Period	30 Sep 2025

Media coverage

Title	Novartis receives FDA approval for Rhapsido (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)
Media name/outlet	Wallstreet Online
Country/Territory	Germany
Date	30/09/25
URL	ct.moreover.com/?a=57824716180&p=1gw&v=1&x=bblrvV5uXrnMlCuDb98vxg
Persons	Mark Lebwohl